Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Q1 2019 Earnings Conference Call - Final Transcript
May 08, 2019 • 04:30 pm ET
Good afternoon, ladies and gentlemen, and welcome to the Tetraphase Pharmaceuticals First Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Ms. Jennifer Viera, Corporate Communications. Go ahead.
Good afternoon, and thank you for joining us today. With me on the call today are Guy MacDonald, President and Chief Executive Officer; Larry Edwards, Chief Operating Officer; Dr. Larry Tsai, Chief Medical Officer; Chris Watt, Senior Vice President of Finance; and Dr. Jacques Dumas, Chief Scientific Officer. On today's call, Guy will make introductory remarks, highlighting recent corporate developments; Larry Edwards will provide an update on the XERAVA launch; Dr. Larry Tsai will provide an update on our pipeline and conference attendance; and Chris will provide an overview of our first quarter 2019 financial results. Guy will then conclude and open the call to questions.
Before we begin our formal comments, however, let me remind you that during today's conference call, we will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's press release and the company's filings with the SEC, which could cause actual results to differ materially from those in such forward-looking statements. Information discussed on today's call is accurate as of today, and we do not necessarily intend to update the specific information in the future.
I would now like to turn the call over to Guy MacDonald. Guy?
Thank you, Jennifer, and good afternoon to everyone. Thank you for joining us on today's call. Before I get into our formal remarks, I'd like to acknowledge the recent increased public recognition around the growing threat of antibiotic resistance and the urgent need for new therapies to address multidrug-resistant infections. Despite this growing threat and awareness the number of new treatments in development remains alarmingly small relative to other therapeutic areas. The challenges facing drug developers in this field are clear, and appropriate incentives to remove barriers to development and stimulate innovation in the antibiotic space are needed to improve the treatment paradigm to ensure patients receive the best care for these life-threatening infections. But regardless of potential policy changes or any future incentivization, we already face a critical need for new antibiotics today, and this need is not diminishing, particularly with the growing threat of antibiotic resistance and identification of new so-called superbugs.
This critical need for new antibiotics provides an opportunity for companies like Tetraphase. In brief, we believe we have the right formula to succeed. Our lead product, XERAVA, which we launched in the U.S. late last year is a well-differentiated product with broad labeling that we've priced appropriately and that we expect will become an increasingly important component of the antibiotic treatment arsenal for the complicated intraabdominal infection or cIAI. In addition, we are very conscious of managing our burn rate and have build a small